-
Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc. et al DC CAFC
- 1:10-cv-00892
- D. Del.
- Judge: Leonard P. Stark
- Filed: 10/18/2010
- Closed: 05/25/2012
- Latest Docket Entry: 07/03/2019
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
0
Accused
Products
1
Patent-in-Suit
586
Days in
Litigation
-
Mylan Pharmaceuticals Inc. v. Galderma Laboratories Inc. et al DC CAFC
- 1:10-cv-00892
- D. Del.
- Judge: Leonard P. Stark
- Filed: 10/18/2010
- Closed: 05/25/2012
- Latest Docket Entry: 07/03/2019
- PACER
- Docket updated daily
Cause of Action
Declaratory Judgment
Patent Invalidity
Patent Non-Infringement
Patent Non-Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
An oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml, the composition consisting of (i) an immediate release (IR)
view more
|
Valid
Entry 182 |
2 |
The composition of claim 1 in which the IR portion is in the form of pellets.
|
Valid
Entry 182 |
3 |
The composition of claim 2 in which the pellets are contained in a capsule.
|
Valid
Entry 182 |
4 |
The composition of claim 1, which at a once-daily dosage will give steady state blood levels of the doxycycline of between 0.3 μg/ml to 0.8 μg/ml.
|
Valid
Entry 182 |
5 |
The composition of claim 1 wherein the one or more pharmaceutically acceptable excipients is a binder, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, and combinations thereof.
|
Valid
Entry 182 |
7 |
The composition of claim 5 wherein the disintegration agent is selected from the group consisting of cornstarch, pregelatinized starch, cross-linked carboxymethylcellulose, sodium starch glycolate, and cross-linked polyvinylpyrrolidone.
|
Valid
Entry 182 |
8 |
The composition of claim 5 wherein the filling agents are selected from the group consisting of lactose, calcium carbonate, calcium phosphate, calcium sulfate, microcrystalline cellulose, dextran, starches, sucrose, xylitol, lactitol, mannitol,
view more
|
Valid
Entry 182 |
9 |
The composition of claim 5 wherein the surfactants are selected from the group consisting of sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, bile salts, and glyceryl monostearate.
|
Valid
Entry 182 |
13 |
The oral pharmaceutical composition of claim 2, wherein the pellets of the IR portion constitute about 80 percent to about 70 percent of the total pellets in the composition.
|
Valid
Entry 182 |
14 |
The oral pharmaceutical composition of claim 13, wherein the pellets of the IR portion constitute about 75 percent of the total pellets in the composition.
|
Valid
Entry 182 |
15 |
A method for treating rosacea in a mammal in need thereof, comprising administering to the mammal a daily dose of an oral pharmaceutical composition of doxycycline, which at a once-daily dosage will give steady state blood levels of doxycycline of a
view more
|
Valid
Entry 182 |
16 |
The method of claim 15, wherein the mammal is a human.
|
Valid
Entry 182 |
17 |
The method of claim 15, wherein the pellets of the composition are contained in a capsule.
|
Valid
Entry 182 |
18 |
The method of claim 15, which at a once-daily dosage, administration of the composition will give steady state blood levels of the doxycycline of between 0.3 μg/ml to 0.8 μg/ml.
|
Valid
Entry 182 |
19 |
The method of claim 15, wherein the one or more pharmaceutically acceptable excipients of the composition is a binder, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, and combinations thereof.
|
Valid
Entry 182 |
20 |
A process for preparing an oral pharmaceutical composition, which at a once-daily dosage will give steady state blood levels of doxycycline of a minimum of 0.1 μg/ml and a maximum of 1.0 μg/ml, consisting of combining (i) an immediate release (IR)
view more
|
Valid
Entry 182 |
21 |
The process of claim 20 wherein the one or more pharmaceutically acceptable excipients is a binder, a disintegration agent, a filling agent, a surfactant, a solubilizer, a stabilizer, and combinations thereof.
|
Valid
Entry 182 |
-
Infringement
Mylan Pharmaceuticals Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
ANDA 90-855 ProductOracea | US 7,749,532 B2 |
1, 2, 3, 4, 5, 7, 8, 9, 13, 14, 15, 16, 17, 18, 19, 20, 21
|
Infringement
Entry 182
|